Effects of Early Use of Nitazoxanide in Patients with COVID-19

niversidade Federal do Rio de Janeiro-UFRJ0 个研究点开始时间: 2020年8月24日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Will be included in the study of patients of both genders who meet all of the following requirements: clinical scenario compatible with infection by the SARS-CoV-2 [Characteristic symptoms of COVID-19 (fever and / or drought and / or fatigue), beginning 1 to 3 days before inclusion in the study; age equal or superior to 18 years; willingness to receive study treatment; providing written and informed consent or the same consent signed by a family member.

•Individuals who meet at least one of the following criteria will be excluded from the study: negative result of RT-PCR for SARS-COV2 collected on admission; impossibility to use oral medications; history of severe liver disease (Child Pugh C class); previous renal failure: patients undergoing dialysis; severe heart failure (NYHA 3 or 4); COPD (GOLD 3 and 4); neoplasia in the last 5 years; known autoimmune disease; individuals with known hypersensitivity to study drugs; previous treatment with the study medication during the last 30 days; clinical suspicion of tuberculosis and bacterial pneumonia.

发起方

niversidade Federal do Rio de Janeiro-UFRJ